Quintas-Cardama et al developed a score for evaluating a patient with the therapy-related myelodysplastic syndrome (MDS). The score can help to identify a patient who may require more aggressive management. The authors are from the University of Texas M.D. Anderson Cancer Center and University of Ulsan in Korea.
Patient selection: therapy-related myelodysplastic syndrome, with previous history of chemotherapy and/or radiation therapy for cancer
Outcome: overall survival and leukemia-free survival
Parameters:
(1) age in years
(2) ECOG performance status (from 0 to 4)
(3) WHO classification
(4) cytogenetics
(5) hemoglobin in g/dL
(6) platelet count in 10^9/L
(7) red blood cell transfusion dependency
|
Parameter |
Finding |
Points |
|
age in years |
< 65 years |
0 |
|
|
>= 65 years |
1 |
|
ECOG performance status |
0 or 1 |
0 |
|
|
2, 3 or 4 |
1 |
|
WHO classification |
RARS, RAEB-1, RAEB-2 |
1 |
|
|
other |
0 |
|
cytogenetics |
unfavorable (-7, complex) |
1 |
|
|
other |
0 |
|
hemoglobin |
>= 11 g/dL |
0 |
|
|
< 11 g/dL |
1 |
|
platelet count |
>= 50 *10^9/L |
0 |
|
|
< 50 * 10^9/L |
1 |
|
transfusion dependent |
no |
0 |
|
|
yes |
1 |
number of risk factors =
= SUM(points for all 7 parameters)
Interpretation:
• minimum score: 0
• maximum score: 7
• The higher the score the worse the overall survival.
|
Total Score |
Prognosis |
Overall Survival (median) |
|
0 to 2 |
good |
34 months |
|
3 or 4 |
intermediate |
12 months |
|
5 to 7 |
poor |
5 months |
Specialty: Hematology Oncology, Clinical Laboratory
